EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Improved adequacy of levothyroxine treatment in low-risk differentiated thyroid cancer using the 2025 ATA criteria: a multicenter real-world analysis of 1,016 patients

Juan J Díez iD, Emma Anda, Victoria Alcazar, Juan C Galofré iD, Cristina Familiar, María J Pamplona-Civera, Silvia González-Martínez, Ana Herrero-Ruiz, María R Alhambra, Alejandra Planas, Cecilia Sánchez-Ragnarsson, Tomás Martín-Hernández und 5 weitere

European Thyroid Journal · 01.06.2026 · 15 (3)

DOI: 10.1530/etj-26-0066 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Thyroid Journal, online erschienen am 01.06.2026. Verfasst von Juan J Díez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain. Hauptthemen laut MEDLINE: Thyroxine, Thyroid Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levothyroxine titration is essential in low-risk differentiated thyroid cancer (DTC).

Objective

To compare levothyroxine treatment adequacy, response distribution, and determinants of inadequacy in a large real-world cohort applying the 2015 versus 2025 American Thyroid Association (ATA) criteria.

Methods

We conducted a multicenter, retrospective cohort study including 1,016 adults with low-risk DTC (median follow-up: 79 months). Dynamic risk stratification and levothyroxine treatment adequacy – defined according to framework-specific thyrotropin (TSH) targets – were assessed at 12 months and at the last visit. Secondary outcomes included rates of overtreatment and undertreatment. Multivariable logistic regression identified factors associated with adequacy among excellent or indeterminate responders.

Results

Under the ATA-2025 criteria, the proportion of patients with an excellent response increased to 72.0% at 12 months and 86.9% at last visit, compared with 62.3 and 77.8% using the ATA-2015 criteria. Treatment adequacy changed from 26.0% at 12 months and 39.6% at the last follow-up visit with ATA-2015 to 40.7 and 67.4% with ATA-2025 (both P < 0.001). Under ATA-2015, inadequacy was driven by overtreatment among excellent responders (61.8% at 12 months; 30.5% at final evaluation) and undertreatment among indeterminate responders (48.4%; 62.2%). Applying the ATA-2025 criteria reclassified overtreated excellent responders as 51.9 and 25.5% and undertreated indeterminate responders as 6.6 and 8.8%, respectively. At the last visit, older age modestly favored adequacy (OR: 1.02 per year, 1.00–1.03) and levothyroxine dose instability strongly predicted inadequacy (OR: 0.12 for adequacy, 0.08–0.16).

Conclusion

Applying the ATA-2025 criteria increases the proportion of patients classified as having adequate TSH control and decreases the proportion labeled as over- or undertreated under the 2015 framework, reflecting the broader, risk-adapted TSH targets introduced in 2025.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineThyroid NeoplasmsHumansRetrospective StudiesFemaleMiddle AgedMaleAdultThyrotropinAgedTreatment OutcomeOvertreatmentUndertreatment

Stichwörter der Autor:innen

ATA guidelinesdifferentiated thyroid cancerdynamic risk stratificationlevothyroxine therapythyrotropin suppressiontreatment adequacy

Substanzen

ThyroxineThyrotropin

Autor:innen und Institutionen

  • Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain.
  • Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana, Majadahonda, Spain.
  • Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
  • Department of Endocrinology, Hospital Universitario de Navarra, Pamplona, Spain.
  • Department of Endocrinology, Hospital Severo Ochoa, Leganés, Spain.
  • Department of Endocrinology, Clínica Universidad de Navarra, Pamplona, Spain.

ORCID-Profile: Juan J Díez, Juan C Galofré

Zitieren

APA

Díez, J. J., Anda, E., Alcazar, V., Galofré, J. C., Familiar, C., Pamplona-Civera, M. J., González-Martínez, S., Herrero-Ruiz, A., Alhambra, M. R., Planas, A., Sánchez-Ragnarsson, C., Martín-Hernández, T., Rodriguez-Jiménez, B., Mora, M., Orois, A., Sánchez-Barrera, R., & Sastre, J. (2026). Improved adequacy of levothyroxine treatment in low-risk differentiated thyroid cancer using the 2025 ATA criteria: a multicenter real-world analysis of 1,016 patients. European Thyroid Journal, 15(3). https://doi.org/10.1530/etj-26-0066

Vancouver

Díez JJ, Anda E, Alcazar V, Galofré JC, Familiar C, Pamplona-Civera MJ, et al. Improved adequacy of levothyroxine treatment in low-risk differentiated thyroid cancer using the 2025 ATA criteria: a multicenter real-world analysis of 1,016 patients. European Thyroid Journal. 2026;15(3). doi:10.1530/etj-26-0066

BibTeX
@article{Dez2026,
  author = {Díez, Juan J and Anda, Emma and Alcazar, Victoria and Galofré, Juan C and Familiar, Cristina and Pamplona-Civera, María J and González-Martínez, Silvia and Herrero-Ruiz, Ana and Alhambra, María R and Planas, Alejandra and Sánchez-Ragnarsson, Cecilia and Martín-Hernández, Tomás and Rodriguez-Jiménez, Beatriz and Mora, Mireia and Orois, Aida and Sánchez-Barrera, Reinaldo and Sastre, Julia},
  title = {Improved adequacy of levothyroxine treatment in low-risk differentiated thyroid cancer using the 2025 ATA criteria: a multicenter real-world analysis of 1,016 patients},
  journal = {European Thyroid Journal},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1530/etj-26-0066}
}
Kostenlos starten →